Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 18Phase 1/2 17Phase 1 16Phase 4 3Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Other solid neoplasm 1

Conditions

Breast Neoplasms 2Solid Tumors 1

Interventions

Dexamethasone 12Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Rituximab 6Prednisone 6Letrozole 6Lenalidomide 6Fluorouracil 6Cisplatin 6Carboplatin 6pembrolizumab 5Sodium Chloride 5Ropivacaine 5Human Papillomavirus Recombinant Vaccine nonavalent 5Trastuzumab 4Tamoxifen 4Standard of Care 4Propofol 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4Enoxaparin 4Doxorubicin 4Bortezomib 4Bismuth 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × ribociclib × 1 year × Clear all
NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Pfizer

Phase 4 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡